HomeCompareMGYOY vs ABBV

MGYOY vs ABBV: Dividend Comparison 2026

MGYOY yields 6.22% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MGYOY wins by $21841.43M in total portfolio value
10 years
MGYOY
MGYOY
● Live price
6.22%
Share price
$6.01
Annual div
$0.37
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21841.53M
Annual income
$21,187,077,579.47
Full MGYOY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MGYOY vs ABBV

📍 MGYOY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMGYOYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MGYOY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MGYOY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MGYOY
Annual income on $10K today (after 15% tax)
$528.63/yr
After 10yr DRIP, annual income (after tax)
$18,009,015,942.55/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MGYOY beats the other by $18,008,994,886.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MGYOY + ABBV for your $10,000?

MGYOY: 50%ABBV: 50%
100% ABBV50/50100% MGYOY
Portfolio after 10yr
$10920.82M
Annual income
$10,593,551,175.61/yr
Blended yield
97.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MGYOY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
2.5
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MGYOY buys
0
ABBV buys
0
No recent congressional trades found for MGYOY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMGYOYABBV
Forward yield6.22%3.06%
Annual dividend / share$0.37$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$21841.53M$102.3K
Annual income after 10y$21,187,077,579.47$24,771.77
Total dividends collected$21796.28M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: MGYOY vs ABBV ($10,000, DRIP)

YearMGYOY PortfolioMGYOY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,944$1,243.83$11,550$430.00+$394.00MGYOY
2$15,557$2,776.83$13,472$627.96+$2.1KMGYOY
3$23,406$6,760.37$15,906$926.08+$7.5KMGYOY
4$44,056$19,011.97$19,071$1,382.55+$25.0KMGYOY
5$114,029$66,888.97$23,302$2,095.81+$90.7KMGYOY
6$445,611$323,599.50$29,150$3,237.93+$416.5KMGYOY
7$2,840,508$2,363,704.19$37,536$5,121.41+$2.80MMGYOY
8$31,202,381$28,163,037.45$50,079$8,338.38+$31.15MMGYOY
9$611,638,945$578,252,397.81$69,753$14,065.80+$611.57MMGYOY
10$21,841,531,251$21,187,077,579.47$102,337$24,771.77+$21841.43MMGYOY

MGYOY vs ABBV: Complete Analysis 2026

MGYOYStock

MOL Magyar Olaj- és Gázipari Nyilvánosan Muködo Részvénytársaság, together with its subsidiaries, operates as an integrated oil and gas company in Hungary and internationally. It operates through five segments: Upstream, Downstream, Consumer Services, Gas Midstream, and Corporate and Other. The company is involved in the refining, transportation, and storage of crude oil; wholesale and retail of crude oil products; geothermal energy production; natural gas transmission; feed water and raw water supply; water transportation; refinery and marketing of oil and petrochemical products; importing and exporting of energetical products; warehousing and oil product storage activities; and exploration and production of crude oil, natural gas, and other gas products. It also engages in the provision of transportation, fleet management, and financial services; marketing agency activities; production and distribution of electricity; production and retail trade of lubricants; and retail and wholesale trade of fuels. In addition, the company provides business, accounting, IT, and company services; construction and engineering, pipeline construction, and leasing activities; repair and maintenance services; investment management services; and real estate management services, as well as manufactures and sells machinery and equipment. Further, it engages in the mineral water production and distribution activities; exploration of hydrocarbon; provision of exploration financing, car sharing, firefighting, tourism, oilfield, and rental services; petrochemicals and consumer retail activities, as well as provision of fire, hospitality, and catering services; and operation of café houses. The company was incorporated in 1991 and is headquartered in Budapest, Hungary.

Full MGYOY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MGYOY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MGYOY vs SCHDMGYOY vs JEPIMGYOY vs OMGYOY vs KOMGYOY vs MAINMGYOY vs JNJMGYOY vs MRKMGYOY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.